ClinicalTrials.gg
CompletedNCT01396213Updated Sep 20, 2017

A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease

A Phase 2 interventional study of Larazotide Acetate and placebo in Celiac Disease, sponsored by 9 Meters Biopharma, Inc.. Completed at 62 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-09-20.

Sponsored by 9 Meters Biopharma, Inc. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Aug 2013, 13 years 2 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Sep 2017.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
342
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 103 studies in Celiac Disease with a site in United States — 16 open to participants now, 20 under way, none of them phase 3. Celiac Disease · United States.

Enrollment
4th of 68
342 · median 46
Started
2011
with 2 others
Phase 2
21 of 103
1 open now
Registered
18th of 103
by date
Lead sponsor
8 of 103
9 Meters Biopharma, Inc.

Among the 103 studies in Celiac Disease with a site in United States, this one is the 4th largest by enrollment of the 68 interventional ones that give a count, is one of 3 that started in 2011, is one of 21 in phase 2, and was the 18th registered.

Celiac Disease

353 studies on the registry are indexed under Celiac Disease; 78 are open to participants now.

Browse Celiac Disease studies →

Open to participants now

16 of the 103 studies in Celiac Disease with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 48 Celiac Disease studies recruiting now, 24 (50%) set no upper age limit and 19 (40%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Celiac Disease with a site in United States, or all of them as a file.
02

Study summary

A randomized, double-blind, placebo-controlled Phase 2B study to evaluate the efficacy and safety of Larazotide Acetate in the treatment of patients with celiac disease who have persistent symptoms despite being on a gluten-free diet.

Read the detailed description

This is a double-blind, placebo-controlled Phase 2B study to evaluate the efficacy and safety of three different doses (0.5, 1 and 2 mg TID) of Larazotide Acetate as an adjunct to gluten-free diet in the treatment of patients with celiac disease (CD). The diagnosis of CD must have been established by jejunal biopsy as well as serology at some point in time prior to entry into the study. Patients must have symptoms despite being on a gluten-free diet as defined by a celiac disease domain of the gastrointestinal symptoms rating scale equal to or more than 2.0.

03

Conditions studied

  • Celiac Disease

Browse trials for

Keywords

  • larazotide acetate
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female adults with proven and serology-confirmed celiac disease on a gluten-free diet for at least 12 months
  • measurable serology at screening
  • CeD GSRS score of ≥ 2.0 prior to randomization
  • experiencing symptoms (ie, diarrhea, abdominal pain, bloating, nausea, or stomachache)
  • willing to maintain current diet gluten-free diet throughout the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • celiac disease or severe complications of celiac disease (eg, EATL, ulcerative jejunitis, perforation, etc.)
  • chronic active GI disease other than celiac disease
  • diabetes (Type 1 or 2) or other disease that might interfere with the conduct of the study
  • value \< 8.5 g/dL
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
342 participants (actual)

Study arms

  • Experimental
    Larazotide Acetate 0.5 mg

    larazotide acetate 0.5 mg capsules TID

    Drug: Larazotide Acetate

  • Experimental
    Larazotide Acetate 1 mg

    larazotide acetate 1 mg capsules TID

    Drug: Larazotide Acetate

  • Experimental
    Larazotide Acetate 2 mg

    larazotide acetate 2 mg capsules TID

    Drug: Larazotide Acetate

  • Placebo comparator
    Placebo

    placebo capsules TID

    Drug: placebo

Interventions

  • gelatin capsule

    Also known as: AT-1001, INN-202

  • Drugplacebo

    gelatin capsule

06

What researchers measure

Primary outcomes

  1. Assess the efficacy of larazotide acetate versus placebo for the treatment of celiac disease in adults as an adjunct to a gluten-free diet

    The primary efficacy endpoint was average on-treatment (Baseline to Week 12) score of theCeliac Disease Gastrointestinal Symptom Rating Scale (CeD GSRS).

    Time frame: CeD GSRS was completed weekly Baseline through the end of 12-week double-blind treatment period.

Secondary outcomes

  1. Assess the safety and tolerability of larazotide acetate in subjects with active celiac disease

    Safety endpoints assessed in this study were adverse events, vital signs, physical examination results, clinical laboratory test results, concomitant medication usage and ECG results

    Time frame: Up to 12 weeks

  2. Validate a CeD PRO diary instrument in subjects with celiac disease

    The CeD PRO is a 12-item questionnaire that was developed to assess symptom severity in clinical trials in subjects with celiac disease. Items in the questionnaire were formulated based on one-on-one interviews with subjects with celiac disease and thus reflect the symptoms that subjects consider part of their celiac disease experience. Subjects rated their symptom severity on an 11-point (0-10) scale. Symptoms included abdominal cramping, abdominal pain, bloating, constipation, diarrhea, gas, loose stools, nausea, vomiting, headache, and tiredness. The questionnaire was designed as a self-administered daily diary, to be completed at the same time each day, and required \< 10 minutes to complete.

    Time frame: The CeD PRO was administered daily throughout the study.

  3. Compare various efficacy endpoints during 12 weeks of double-blind treatment

    Additional efficacy assessments comprised a variety of known scales used for evaluating subjects with celiac disease, including the Gastrointestinal Symptoms Rating Scale (GSRS), Bristol Stool Form Scale (BSFS), Short Form 12 health survey Version 2 (SF12v2), Celiac Disease Quality of Life (CeD-QoL) scale, and the Clinical Global Assessment (CGA). A Gluten-Free Diet Compliance Questionnaire (GFDCQ) and Celiac Dietary Adherence Test (CDAT) were also included to assess compliance with the gluten-free diet.

    Time frame: GSRS - weekly; BSFS - daily; CGA - screening, baseline, Week 12 and follow-up visits; CeD-QoL and SF12v2 - start of placebo run-in, Week 12 and follow-up visits; CD and CFDCQ - follow-up visit.

07

Study locations

62 sites
  • Birmingham, Alabama 35209, United States
  • Mesa, Arizona 85206, United States
  • Tucson, Arizona 85704, United States
  • Oceanside, California 92056, United States
  • Orange, California 92868, United States
  • San Francisco, California 94115, United States
  • Santa Monica, California 90404, United States
  • Walnut Creek, California 94598, United States
  • Denver, Colorado 80222, United States
  • Boynton Beach, Florida 33426, United States
  • Edgewater, Florida 32132, United States
  • Orlando, Florida 32806, United States
  • Summerfield, Florida 34491, United States
  • Marietta, Georgia 30067, United States
  • Chicago, Illinois 60612, United States
  • Rockford, Illinois 61107, United States
  • West Des Moines, Iowa 50266, United States
  • Wichita, Kansas 67207, United States
  • Lexington, Kentucky 40536, United States
  • Louisville, Kentucky 40202, United States
  • Baltimore, Maryland 21229, United States
  • Hagerstown, Maryland 21742, United States
  • Boston, Massachusetts 02215, United States
  • Chesterfield, Michigan 48047, United States
  • Wyoming, Michigan 49519, United States
  • Duluth, Minnesota 55805, United States
  • Rochester, Minnesota 55905, United States
  • Jackson, Mississippi 39202, United States
  • Saint Louis, Missouri 63141, United States
  • Missoula, Montana 59808, United States
  • Las Vegas, Nevada 89119, United States
  • Marlton, New Jersey 08053, United States
  • Lake Success, New York 11042, United States
  • New York, New York 10016, United States
  • New York, New York 10032, United States
  • Rochester, New York 14618, United States
  • Cary, North Carolina 27518, United States
  • Salisbury, North Carolina 28144, United States
  • Winston-Salem, North Carolina 27103, United States
  • Cleveland, Ohio 44195, United States
  • Mentor, Ohio 44060, United States
  • Oklahoma City, Oklahoma 73160, United States
  • Portland, Oregon 97210, United States
  • Bethlehem, Pennsylvania 18017, United States
  • Perkasie, Pennsylvania 18944, United States
  • Philadelphia, Pennsylvania 19107, United States
  • Pittsburgh, Pennsylvania 15243, United States
  • Warwick, Rhode Island 02886, United States
  • Chattanooga, Tennessee 37421, United States
  • Dallas, Texas 75321, United States
  • San Antonio, Texas 78229, United States
  • Saint George, Utah 84790, United States
  • Salt Lake City, Utah 84109, United States
  • Alexandria, Virginia 22304, United States
  • Charlottesville, Virginia 22911, United States
  • Seattle, Washington 98104, United States
  • Edmonton, Alberta T6G2X8, Canada
  • Abbotsford, British Columbia V2T3R7, Canada
  • Kelowna, British Columbia V1Y1Z9, Canada
  • Vancouver, British Columbia V6Z2K5, Canada
  • Victoria, British Columbia V8V3P9, Canada
  • Hamilton, Ontario L854J9, Canada
08

References and documents

Publications

  • Leffler DA, Kelly CP, Green PH, Fedorak RN, DiMarino A, Perrow W, Rasmussen H, Wang C, Bercik P, Bachir NM, Murray JA. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology. 2015 Jun;148(7):1311-9.e6. doi: 10.1053/j.gastro.2015.02.008. Epub 2015 Feb 13. PubMed 25683116 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2011 to primary completion in Aug 2013, 21 months.

Of 24 phase 2 interventional studies under Celiac Disease, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 28. This study's 21 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2011
First posted
Jul 18, 2011
StartActual
Nov 7, 2011
Primary completionActual
Aug 20, 2013
CompletionActual
Aug 20, 2013
Results delay requested
Sep 11, 2017
Last update
Sep 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01396213
Lead sponsor
9 Meters Biopharma, Inc.
Responsible party
Sponsor
First posted
Jul 18, 2011
Start date
Nov 7, 2011
Primary completion
Aug 20, 2013
Completion
Aug 20, 2013
Last update
Sep 20, 2017

Study contacts

Henrik Rasmussen, MD, PhD
study director · Sponsor GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Larazotide acetate

Start the discussion